« Return to News | Study Conduct | Drug Sponsors

Yale and Gilead Sciences announce cancer research collaboration

Wednesday, March 30, 2011 01:40 PM

California-based Gilead Sciences and Yale School of Medicine have announced a research collaboration focused on the discovery of new cancer therapies, according to FierceBiotech.

"The collaboration brings together one of the world's top research universities and a biopharmaceutical company dedicated to addressing unmet medical needs with the goal of finding new treatments for cancer," president of Yale Richard C. Levin said.

Initially, the partnership will span four years and includes an option to renew for up to ten years. Gilead will support the endeavor with $40 million in research support and basic science infrastructure development for the first four years; it may provide up to $100 million over ten years if the pact continues. Gilead has the first option to license resulting inventions from the collaboration.

"Following Gilead's recent acquisitions of cancer development programs, this partnership serves to strengthen our discovery capabilities in the area of oncology," said Norbert W. Bischofberger, Ph.D., Gilead's executive vice president, research and development and chief scientific officer. "Based on the strong track-record of the Yale cancer research team, I am confident this collaboration will lead to important advances in the understanding of the genetic basis of cancer as we collectively seek to develop novel targeted therapies for patients in areas of unmet medical need."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.